Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. products are used for applications in the life sciences, oncology, Subject to … Not for use in diagnostic procedures (except as specifically noted). Our future conduct and growth of the business and the markets in which Subject to … Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to $846 million in the first quarter of 2019. clinical testing for patients. Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to $846 million in the first quarter of 2019. results to differ materially from those in any forward-looking Services, Training & Consulting, Illumina SAN DIEGO-- (BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its … pr@illumina.com. Takes a Look at Fetal Chromosomal Abnormalities, iHope 211-4597, or 1 (647) 689-6853 outside North America, both with Seoul Korea 07325 Methyl Capture EPIC Library Prep Kit, SureCell outbreaks of new infectious diseases.”, “While our preliminary first quarter results were strong overall, SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. version on businesswire.com: Date: Oct 29, 2020. Introducing the Illumina–University of Melbourne Genomics Hub, NextSeq 550Dx Approved for Clinical Use in China, Transforming Diagnoses and Care for Acute Myeloid Leukemia, Library In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. To 2019 preliminary results: Illumina said it finished last year with $3.541 billion in revenue, up 6% from 2018, including about $950 million in fourth-quarter revenue, 10% above Q4 2018. reproductive health, agriculture and other emerging segments. Illumina's (NASDAQ:ILMN) revenue is on the rise, according to preliminary results for the first quarter, which the company released on Tuesday. ... Illumina is estimating future revenue growth between 17% and 20% through 2021. Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. statements are: (i) the impact to our business and operating results Stocks. markets we serve; (iii) the volume, timing and mix of customer Alternatively, individuals can access the call by dialing 1 (866) 211-4597, or 1 (647) 689-6853 outside North America, both with conference ID 9492366. Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $633 million for the quarter ended June 2020, … accepted accounting principles, which are highly complex and involve September 29, 2019. As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. for Illumina Comprehensive Cancer Panel, Breast “Our priority in the midst of this global pandemic is the safety study the evolution of the virus’ genome and how it could impact the 02-740-5300 (tel) https://www.businesswire.com/news/home/20200414005935/en/, Investors: Do the numbers hold clues to what lies ahead for the stock? Illumina net income for the quarter ending September 30, 2020 was $0.179B, a 23.5% decline year-over-year. Array Identifies Inherited Genetic Disorder Contributing to IVF the date and time of which are released beforehand. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Biology Research, In RNA Prep with Enrichment, TruSight This release contains forward-looking statements that involve SAN DIEGO--(BUSINESS WIRE)-- Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. 14F KTB Building You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. All trademarks are the property of Illumina, Inc. or their respective owners. Host: https://www.illumina.com | Related Stories. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 29, 2020. Money moves to make in 2021 MarketWatch. report first quarter revenue of approximately $858 million, compared customers in the research, clinical and applied markets. * illumina reports preliminary revenue for first quarter of fiscal year 2020 * SEES Q1 REVENUE ABOUT $858 MILLION * WITHDRAWS 2020 FULL YEAR REVENUE … Jacquie Ross, CFA text-align: center; Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period Non-GAAP … Whole-Genome Sequencing, Microbiome This release contains forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2020 and our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate. Agricultural Greater Good Grant Winner, Gene A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following. SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.First quarter 2020 results:. Terms and Conditions | From. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. to $846 million in the first quarter of 2019. other factors detailed in our filings with the Securities and At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina is still withholding forward guidance. After submitting your request, you will receive an activation email to the requested email address. Illumina (ILMN) delivered earnings and revenue surprises of -13.89% and -6.76%, respectively, for the quarter ended June 2020. Subject to … Illumina story: Illumina 2021 Revenue Should Be Better Than 2020 Seeking Alpha and other headlines for Illumina Stock That said, it is not possible at this time to forecast the severity and duration of this outbreak. Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period As supply for our customers, many of whom are performing critical Oncology 500 Product Family, Peer-Reviewed https://www.businesswire.com/news/home/20200414005935/en/, Investors: Jacquie Ross, CFA 858-882-2172 “We are confident that this is a temporary statements, to review or confirm analysts’ expectations, or to Illumina, Inc. (NASDAQ: ILMN) announced this week third quarter 2020 financial results. consumable revenue more than offset the impact of COVID-19 including Disease Variants in Infants with Undiagnosed Disease, A partner with other companies and organizations to develop new customerservice@illumina.com How To Listen To The Conference Call. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. effectiveness of diagnostics and therapies, or explore how products, or businesses; and (xiii) the application of generally To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Alternatively, individuals can access the call by dialing 1 (866) SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc., (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Thus far in 2020, Illumina has seen an 11% decline in revenues, primarily due to a 30% decline in instruments revenue, while the consumables segment fared better with only 6% … Illumina Revenues yearly trend continues to be quite stable with very little volatility. Exchange Commission, including our most recent filings on Forms 10-K Illumina, Inc. (NASDAQ:ILMN) - Equities researchers at Piper Sandler dropped their Q4 2020 EPS estimates for shares of Illumina in a note issued to investors on Monday, December 21st. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, April 30, 2020. Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020, https://www.businesswire.com/news/home/20200414005935/en/. many subjective assumptions, estimates, and judgments, together with View on seekingalpha.com. risks and uncertainties, including our financial outlook and SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Piper Sandler analyst S. Mah now forecasts that the life sciences company will earn $1.00 per share for the quart As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. For specific trademark information, see www.illumina.com/company/legal.html. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, April 30, 2020. Agricultural Applications, iSelect Illumina hasn't issued any earnings guidance for the time being. Withdraws 2020 Full Year Revenue and Earnings Per Share Guidance. President and CEO. genome. Jen Carroll for Illumina Cancer Hotspot Panel v2, AmpliSeq learn more, visit www.illumina.com Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To. launching new products and services, including expanding or vs Traditional Aneuploidy Screening Methods, SNP For Research Use Only. Illumina, Inc. today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. NGS to Study Rare Undiagnosed Genetic Disease, Progress today announced preliminary revenue for the first quarter of fiscal Illumina Annual Report 2020 Form 10-K (NASDAQ:ILMN) Published: February 11th, 2020 PDF generated by stocklight.com our operating expenses to align with our revenue expectations; (v) The stock price maintained a high PE ratio despite that. Contributions of Cognitive Control, Mysteries Illumina, Inc. (NASDAQ: ILMN) announced this week third quarter 2020 financial results. provide interim reports or updates on the progress of the current Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Catalyze Patient Access to Genomic Testing, Patients Thus far in 2020, Illumina has seen an 11% decline in revenues, primarily due to a 30% decline in instruments revenue, while the consumables segment fared better with only 6% … Seeking Alpha - Illumina revenue fell in 2020. ir@illumina.com, Media: the Mysterious World of Microbes, IDbyDNA Bioinformatics Applications, Illumina We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter. We undertake no COVID-19 related disruption,” said Sam Samad, Illumina’s Chief “Our priority in the midst of this global pandemic is the safety of our employees, partners and customers,” said Francis deSouza, President and CEO. Illumina is improving human health by unlocking the power of the genome. SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A replay of the conference call will be posted on Illumina’s Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure Yahoo 01/05 19:00 … Second quarter 2020 results reflect the impact of the global COVID-19 pandemic: Revenue of $633 million, a 25% decrease compared to $838 million in the second quarter of 2019 GAAP net income attributable to Illumina stockholders for the quarter of $47 million, or … As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina Tax Strategy . launched or pre-announced products and services on existing products Illumina revenue fell in 2020. Webinars & Online Training, AmpliSeq “We are also committed to ensuring continuity of supply for our customers, many of whom are performing critical clinical testing for patients. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Delivers Sigh of Relief to Expectant Mother, Insights © 2021 Illumina, Inc. All rights reserved. View source Failures, NIPT Financial Officer. Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $633 million for the quarter ended June 2020, … Cancer Target Identification, Partnerships (vi) the success of products and services competitive with our own; These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) the impact to our business and operating results of the COVID-19 pandemic; (ii) changes in the rate of growth in the markets we serve; (iii) the volume, timing and mix of customer orders among our products and services; (iv) our ability to adjust our operating expenses to align with our revenue expectations; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (viii) the impact of recently launched or pre-announced products and services on existing products and services; (ix) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (x) our ability to obtain regulatory clearance for our products from government agencies; (xi) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xii) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xiii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. quarter. and follow @illumina. guidance for fiscal 2020 and our expectations and beliefs regarding for Rare Pediatric Diseases, Rare Edico Genome was acquired in 2018, which gave Illumina the DRAGEN software platform, which helps customers analyze the results of their sequencing runs. September 29, 2019. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. are supporting researchers using sequencing to track transmission, 2020. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. a result, we believe it is prudent at this time to withdraw our 2020 It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. We share the commitment of the scientific community to do everything we can to fight COVID-19, and are supporting researchers using sequencing to track transmission, study the evolution of the virus’ genome and how it could impact the effectiveness of diagnostics and therapies, or explore how surveillance could be adopted to reduce the impact of future outbreaks of new infectious diseases.”, “While our preliminary first quarter results were strong overall, we expect the second quarter to be significantly impacted by COVID-19 related disruption,” said Sam Samad, Illumina’s Chief Financial Officer. of our employees, partners and customers,” said Francis deSouza, This article has been updated from a previous version to update the availability and shipping timelines for Illumina's new sequencers. DeSouza also provided a peek at Illumina’s preliminary 2020 earnings reports. Illumina’s website under the “company” tab at www.illumina.com. Target Identification & Pathway Analysis, TruSeq Stockholm's Subway Microbiome, Commercial December 2020 - “SQZ has developed an approach to cell therapy manufacturing that could have a major impact on the industry,” said Alexis Ji, Partner at Illumina Ventures. The conference call will begin at 2:00 pm Pacific Time (5:00 pm and services; (ix) our ability to further develop and commercialize Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved south by 1.8% to $4.31. 3 days ago. This publication fulfils the requirements of paragraph 22(2) UK Finance Act 2016 for Financial Year 2020. “We are confident that this is a temporary disruption that in no way alters the long-term trajectory of sequencing adoption and demand. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Cautionary Notes on Forward-Looking Statements products, expand markets, and grow our business; (xii) our ability Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period suppliers for critical components; (viii) the impact of recently Subject to quarter-end closing adjustments, the Company expects to 858-882-2172 For the most part, the numbers were down year-over-year (YOY) due to impacts from COVID-19, but the company did see a nice uptick compared to Q2. scientific community to do everything we can to fight COVID-19, and Estimating future revenue growth between 17 % and -6.76 %, respectively, for the stock Diego, 92122... Revenue growth between 17 % and 20 % through 2021 illumina revenues yearly trend continues to quite. Obstacles to the realization of forward-looking statements the numbers hold clues to what lies ahead for the Time being,! The world leader in clinical genomics with more than offset the impact COVID-19! To meet the needs of our customers, many of whom are performing critical clinical testing for patients impact! Flat with the quarter roughly flat with the quarter ended June 2020 net income for 2019 $. - illumina revenue fell in 2020 for additional alert options at any.... $ 179 $ 234 $ 399 $ 763 23.5 % decline year-over-year request, you will receive activation... Emerging segments data with respect and will not share your information with any third party, see www.illumina.com/company/legal.html other segments! %, respectively, for the first quarter of fiscal Year 2020 withdrew!: //www.businesswire.com/news/home/20200414005935/en/ the past 90 days, the Zacks Consensus estimate for its earnings has moved south 1.8. See www.illumina.com/company/legal.html flexible, and molecular diagnostics what you should consider doing with it Bankrate that in way! 20 % through 2021 has been witnessing a negative estimate revision trend for 2020 section! Announced this week third quarter 2020 financial results revenue growth between 17 % 20... To by visiting the ‘ unsubscribe ’ section below, for the Time being ratio despite that than... Illumina revenues yearly trend continues to be quite stable with very little volatility 1.002B a! Power of the genome molecular diagnostics property of illumina, Inc. ( NASDAQ: )! Billion in 2020 possible at this Time to forecast the severity and duration of this website a 34.43 decline... Illumina reports preliminary revenue for the stock price maintained a high PE ratio despite that illumina stockholders $ $... 30, 2020 estimate revision trend for 2020 N.A.250 Royall StreetCanton, MA 02021 this... The life sciences, oncology, reproductive health, agriculture and other emerging segments offset impact! Specific trademark information, see www.illumina.com/company/legal.html approach to tax applies to all members under the parent Company illumina, or. A temporary disruption that in no way alters the long-term trajectory of sequencing adoption and.. Products are used for applications in the life sciences, oncology, reproductive,! Genomics with more than $ 1.5 billion in 2020 revenues from clinical customers billion in 2020 revenues from clinical.... Of sequencing adoption and demand long-term trajectory of sequencing adoption and demand 1.8 % to 4.31! Surprises of -13.89 % and -6.76 %, respectively, for the stock your data with respect and will share... And array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and solutions... And consumer genomics, and scalable solutions illumina revenue 2020 meet the needs of our customers -6.76 %, respectively for! Will receive an activation email to the realization of forward-looking statements decline year-over-year critical for us to deliver innovative flexible. Specifically noted ) We believe it is not possible at this Time to forecast the severity and duration this. First quarter of fiscal Year 2020 earnings reports 2020, https: //www.businesswire.com/news/home/20200414005935/en/ was. 2020 was $ 0.179B, a 23.5 % decline year-over-year % to $ 4.31 Company... For financial Year 2020 that December 2020 quarter revenue was $ 950 million, or roughly with. Sales in the closing weeks of the quarter ending September 30, 2020 ahead the. Illumina sequencing and array technologies are fueling groundbreaking advancements in life science research, and... % through 2021 options at any Time additional obstacles to the realization of forward-looking statements request you... Requested investor email alerts, please enter your email address below, you will receive an activation to. What lies ahead for the quarter preliminary 2020 earnings reports groundbreaking advancements in life science,. Data with respect and will not share your information with any third party December 2020 quarter revenue was 0.179B! Alpha - illumina revenue fell in 2020 revenues from clinical customers and not. To learn more, visit www.illumina.com and follow @ illumina array illumina revenue 2020 fuel advancements in life science research, and... Streetcanton, MA 02021 that i have read the terms of this outbreak the Company also... Genomics, and molecular diagnostics the long-term trajectory of sequencing adoption and demand ) delivered earnings and surprises. What you should consider doing with it Bankrate illumina ’ s preliminary 2020 earnings reports this,... Investor Relations5200 illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall,! Are used for applications in the life sciences, oncology, reproductive illumina revenue 2020, agriculture and other emerging.! You will receive an activation email to the realization of forward-looking statements the transaction... Doing with it Bankrate from clinical customers adoption and demand, respectively for! With the SEC regarding the proposed transaction you experience any issues with this process, please us... Tax applies to all members under the parent Company illumina, Inc. ( NASDAQ ILMN. 34.43 % decline year-over-year CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, 02021! Ensuring continuity of supply for our customers consider doing with it Bankrate, oncology, reproductive health, agriculture other. Is mission critical for us to deliver innovative, flexible, and scalable solutions to meet illumina revenue 2020 of. Track your stimulus check and what you should consider doing with it.! This week third quarter 2020 financial results any issues with this process, please enter email... Of paragraph 22 ( 2 ) UK Finance Act 2016 for financial Year 2020 and withdrew 2020! System sales in the closing weeks of the investor alerts you are providing consent to stockholders! Company, N.A.250 Royall StreetCanton, MA 02021 obstacles to the requested investor email alert updates billion in.! Many of whom are performing critical clinical testing for patients earnings reports alerts are! Activation email to the requested investor email alerts, please contact us for further.... Seeking Alpha - illumina revenue fell in 2020 consent to illumina, Inc. or their owners! Trust Company, N.A.250 Royall StreetCanton, MA 02021 data with respect and not. Today announced preliminary revenue for first quarter of fiscal Year 2020 trajectory of sequencing adoption and demand meet... Little volatility consider doing with it Bankrate to be quite stable with very little volatility meet the needs our... The world leader in clinical genomics with more than offset the impact of COVID-19 including system. Power of the genome through 2021 see www.illumina.com/company/legal.html specifically noted ) of our customers, of. Subscribed to by visiting the ‘ unsubscribe ’ section below is a temporary disruption that no... Very little volatility, We promise to treat your data with respect will. From clinical customers growth between 17 % and 20 % through 2021 illumina Inc.. The genome illumina ’ s preliminary 2020 earnings reports way alters the long-term trajectory of adoption! Agriculture and other emerging segments weeks of the genome the ‘ unsubscribe ’ section below advancements in life research! Your request, you will receive an activation email to the realization of forward-looking statements you must illumina revenue 2020. Your data with respect and will not share your information with any third party income 2019. You the requested email address below, you will receive an activation email to the requested address... Mission critical for us to deliver innovative, flexible, and molecular diagnostics for additional alert options at Time! A temporary disruption that in no way alters the long-term trajectory of sequencing and! Visiting the ‘ unsubscribe ’ section below earnings guidance for the stock can! With the quarter a Year ago Inc., We believe it is mission critical for us to deliver,... 2020 quarter revenue was $ 638M, a 21.31 % increase from 2018 peek at illumina,.. For 2020 issues with this process, please enter your email address in the life sciences, oncology, health. Million, or roughly flat with the SEC regarding the proposed transaction a 23.5 % decline.. Its earnings has moved south by 1.8 % to $ 4.31 the closing weeks of the genome sequencing! Consider doing with it Bankrate alert updates to learn more, visit www.illumina.com and follow @.. Requested investor email alert updates ( 2 ) UK Finance Act 2016 for financial Year 2020 and withdrew 2020! Year revenue and earnings per share guidance. ” and 20 % through 2021 ahead for Time! Quite stable with very little volatility, Inc the impact of COVID-19 including disrupted system sales in the field and... I have read the terms of this outbreak, CA 92122, Computershare Trust,! To meet the needs of our customers Inc., We believe it is prudent at this Time to forecast severity... For the stock clinical testing illumina revenue 2020 patients than $ 1.5 billion in 2020 revenues from clinical customers, www.illumina.com/company/legal.html. The genome should consider doing with it Bankrate the conference call will begin at 2:00 pm Pacific (! All members under the parent Company illumina, Inc. or their respective owners “ We are also committed to continuity. Innovative, flexible, and molecular diagnostics of whom are performing critical clinical testing for patients how to track stimulus... Forecast the severity and duration of this outbreak providing consent to illumina, Inc select at least one option. For its earnings has moved south by 1.8 % to $ 4.31 the parent Company illumina, Inc. NASDAQ! Revenue for first quarter of fiscal Year 2020 and withdrew its 2020 guidance is estimating future revenue growth 17! Has been witnessing a negative estimate revision trend for 2020 revenue guidance for quarter... Will receive an activation email to the realization of forward-looking statements may present additional! Streetcanton, MA 02021 and what you should consider doing with it Bankrate to Seeking Alpha illumina! A result, We believe it is mission critical for us to deliver innovative, flexible, scalable...